invendo submits 510(k) application to US FDA
This article was originally published in Clinica
Executive Summary
invendo medical has filed a 510(k) submission with the US FDA seeking market clearance of the company’s C20 colonoscopy system and SC20 single-use colonoscope. The approval application – the firm's first in the US – is based on results from a pivotal trial in 61 subjects, results from which appeared two months ago (www.clinica.co.uk, 5 January 2010). In the trial, lesions were detected in 41% of the subjects, and there were no device-related adverse events. The C20 system is already CE marked in Europe. invendo is based in New York and Kissing, Germany.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?